β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression

@article{Rothstein2005LactamAO,
  title={$\beta$-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression},
  author={Jeffrey D. Rothstein and Sarjubhai Amratbhai Patel and Melissa R. Regan and Christine Haenggeli and Yanhua H. Huang and Dwight E. Bergles and Lin Jin and Margaret Dykes Hoberg and Svetlana Vidensky and Dorothy S. Chung and Shuy-Vang Toan and Lucie I. Bruijn and Zao-zhong Su and Pankaj Gupta and Paul B Fisher},
  journal={Nature},
  year={2005},
  volume={433},
  pages={73-77}
}
Glutamate is the principal excitatory neurotransmitter in the nervous system. Inactivation of synaptic glutamate is handled by the glutamate transporter GLT1 (also known as EAAT2; refs 1, 2), the physiologically dominant astroglial protein. In spite of its critical importance in normal and abnormal synaptic activity, no practical pharmaceutical can positively modulate this protein. Animal studies show that the protein is important for normal excitatory synaptic transmission, while its… 

Harmine, a natural beta-carboline alkaloid, upregulates astroglial glutamate transporter expression

GLT-1 transporter: An effective pharmacological target for various neurological disorders

Mechanism of Ceftriaxone Induction of Excitatory Amino Acid Transporter-2 Expression and Glutamate Uptake in Primary Human Astrocytes*

TLDR
The data indicate that ceftriaxone is a potent modulator of glutamate transport in PHFA through NF-κB-mediated EAAT2 promoter activation, and suggest a mechanism for ceftRIaxone modulation of glutamate Transport and for its potential effects on ameliorating specific neurodegenerative diseases through modulation of extracellular glutamate.

The Effect of GLT-1 Upregulation on Extracellular Glutamate Dynamics

TLDR
The data demonstrate the complexities of glutamate uptake by showing that GLT-1 expression does not necessarily translate to accelerated uptake, and suggest that the mechanisms underlying activity- and regional-dependent differences in glutamate dynamics are independent of GLT1 expression levels.

Current approaches to enhance glutamate transporter function and expression

TLDR
The current status of the search for EAAT2/GLT‐1 activators is described, challenges and limitations that this approach might encounter are addressed and pharmacological activators of the activity of EAAT1/ GLT1 are described as promising tools for neuroprotection.

Parawixin1: A Spider Toxin Opening New Avenues for Glutamate Transporter Pharmacology

TLDR
Because EAAT2 is a key player in determining the extracellular glutamate concentration in the mammalian brain, drugs targeting this protein could prevent glutamate excitotoxicity without blocking glutamatergic transmission.

Novel positive allosteric modulators of glutamate transport have neuroprotective properties in an in vitro excitotoxic model.

TLDR
This work proposes that this compound prevents excess glutamate signaling by increasing the rate of glutamate clearance by EAAT2, thereby preventing excitotoxic damage and cell death, and is therefore an innovative approach for neuroprotection with potential for translation in in vivo animal models of excitOToxicity.
...

References

SHOWING 1-10 OF 35 REFERENCES

Insights into glutamate transport regulation in human astrocytes: Cloning of the promoter for excitatory amino acid transporter 2 (EAAT2)

TLDR
It is raised the intriguing possibility that the EAAT2 promoter may be useful for targeting gene expression in the brain and for identifying molecules capable of modulating glutamate transport that could potentially inhibit, ameliorate, or prevent various neurodegenerative diseases.

Neuroprotective Strategies in a Model of Chronic Glutamate‐Mediated Motor Neuron Toxicity

TLDR
This system provides a preclinical screening method for the burgeoning number of drugs postulated for clinical trials in motor neuron disease and a model to evaluate the mechanisms of chronic glutamate toxicity.

Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity.

TLDR
Selective inhibition of glutamate transport produces a model of clinically relevant slow neurotoxicity and appears to be mediated by the action of non-N-methyl-D-aspartate receptors, which supports the hypothesis that the slow loss of motor neurons in amyotrophic lateral sclerosis could be due to defective glutamate transport.

Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice.

TLDR
The results suggest that the loss of EAAT2 may contribute to, but does not cause, motor neuron degeneration in ALS.

Glutamate uptake

Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis

TLDR
Developing C‐terminal, antioligopeptide antibodies that were specific for each glutamate transporter subtype found that GLT‐1 immunoreactive protein was severely decreased in ALS, both in motor cortex (71% decrease compared with control) and in spinal cord.

A Neuronal Glutamate Transporter Contributes to Neurotransmitter GABA Synthesis and Epilepsy

TLDR
There was a 50% loss of hippocampal GABA levels associated with knockdown ofEAAC1, and newly synthesized GABA from extracellular glutamate was significantly impaired by reduction of EAAC1 expression, indicating decreased tonic inhibition.

Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS

TLDR
Treatment with a selective cyclooxygenase‐2 inhibitor, celecoxib, markedly inhibited production of prostaglandin E2 in the spinal cords of ALS mice, suggesting that cyclo Oxygenase-2 inhibition may benefit ALS patients.

Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis.

TLDR
ALS is associated with a defect in high-affinity glutamate transport that has disease, region, and chemical specificity and could lead to neurotoxic levels of extracellular glutamate and thus be pathogenic in ALS.